Growth hormone deficiency drug from OPKO and Pfizer fails study

(Reuters) – OPKO Health Inc said its experimental drug for growth hormone deficiency (GHD) in adults failed to provide a statistically significant benefit over a placebo in a late-stage study, sending its shares down 14 percent in early trading. GHD is a rare disorder characterized by the inadequate secretion of the growth hormone from the pituitary gland, an organ responsible for the production of multiple hormones. Miami-based OPKO, which is developing the drug, hGH-CTP, with Pfizer Inc, said on Friday it had identified one or more outliers that may have affected the trial, in which patients were given the drug once a week.
Go to Source